WASHINGTON (AP) - Federal health officials have approved an experimental drug to treat psychotic delusions and behaviors that often afflict patients with Parkinson's disease, the debilitating movement disorder. The drug from Acadia Pharmaceuticals Inc. is the first drug for the condition, which affects approximately half of Parkinson's patients. An estimated ... More...
